<DOC>
	<DOCNO>NCT00323856</DOCNO>
	<brief_summary>The purpose study determine immunologic overall safety associate long-term use Alphanate subject diagnose severe hemophilia A ( Factor VIII : C le 0.01 IU/ml ) , previously treat plasma-derived Factor VIII product Alphanate history develop either antibody inhibitor Factor VIII nonspecific inhibitor coagulation .</brief_summary>
	<brief_title>Safety Study Alphanate Previously Treated Patients With Severe Hemophilia A</brief_title>
	<detailed_description>This Phase IV , non-randomized , multicenter study least 50 evaluable subject diagnose severe hemophilia A. Enrolled subject treat home in-clinic therapy exclusively Alphanate sole source Factor VIII concentrate prophylaxis treatment bleed episode surgical procedure . Subjects treat least 2 year minimum 50 exposure day , 50 exposure day reach , maximum 30 month accordance subject 's usual pre-study treatment regimen . Subjects continue treatment develop inhibitor Factor VIII titer great equal 5 Bethesda unit ( BU/ml ) ; Factor VIII become ineffective provide hemostasis , subject exhibit severe serious adverse event prevent completion study .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male At least 6 year age 65 year age . Signed date Informed Consent Form Patient Authorization Release Information approve appropriate Institutional Review Board ( IRB ) prior screen enrollment . If subject minor ( i.e. , less 18 year age ) parent legal guardian must sign date inform consent . Diagnosis severe hemophilia A Levels Factor VIII le 0.01 IU/mL . Treatment cryoprecipitate , Factor VIII concentrate , and/or whole blood , least 150 cumulative exposure day ( CEDs ) prior enrollment . No treatment cryoprecipitate , Factor VIII concentrate , blood product , least 72 hour prior screen . No previous diagnosis inhibitor Factor VIII detectable titer . Subjects must never diagnose nonspecific inhibitor coagulation . Negative test presence Factor VIII inhibitor screen enrollment . CD4 count great equal 400 cells/µL . Vaccination hepatitis A hepatitis B , evidence antibody hepatitis A hepatitis B . ( A subject prior immunity hepatitis A offer course vaccination hepatitis A . ) Karnofsky Performance Score least 50 . Any immunosuppressive medication include intravenous immunoglobulin time enrollment . Clinical sign symptom infection , fever , chill nausea screen enrollment . History frequent reaction Factor VIII concentrate ( e.g. , chill headache ) . Prior treatment Alphanate® ( SolventDetergent/ HeatTreated ) . Immunocompromised ( include HIV+ status impair immune system due disease treatment ) .</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Plasma-derived treatment</keyword>
	<keyword>Factor VIII</keyword>
	<keyword>Inhibitor</keyword>
</DOC>